Rare Cancer News & Clinical Trials » Trial

Trial - Acinar Cell Carcinoma (14 unread)

Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population

Posted: April 15th, 2024, 11:00pm UTC

Conditions: Prostate Cancer; Pathology
Interventions: Procedure: Transperineal Prostate Biopsy
Sponsors: West China Hospital
Not yet recruiting
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

Posted: December 7th, 2023, 1:00am UTC

Conditions: Pancreas Adenocarcinoma; Small-cell Lung Cancer; Glioblastoma, IDH-wildtype
Interventions: Genetic: Long term survival multimodal analysis
Sponsors: Cure 51; Gustave Roussy, Cancer Campus, Grand Paris; Centre Leon Berard; Vall d'Hebron Institute of Oncology; Istituto Europeo di Oncologia; Charite University, Berlin, Germany
Recruiting
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Posted: November 3rd, 2023, 11:00pm UTC

Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8
Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma

Posted: April 26th, 2023, 11:00pm UTC

Conditions: Lung Adenocarcinoma, Stage I
Interventions: Diagnostic Test: Invasiveness diagnosis
Sponsors: Wuhan Union Hospital, China
Recruiting
Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Posted: March 18th, 2022, 11:00pm UTC

Conditions: Pancreatic Acinar Cell Carcinoma
Interventions: Drug: Olaparib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Posted: August 2nd, 2021, 11:00pm UTC

Conditions: Melanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusion; CRAF Gene Fusion; CRAF Fusion; RAF1 Gene Fusion; RAF1 Fusion; Thyroid Cancer, Papillary; Spitzoid Melanoma; Pilocytic Astrocytoma; Pilocytic Astrocytoma, Adult; Non Small Cell Lung Cancer; Non-Small Cell Adenocarcinoma; Colorectal Cancer; Pancreatic Acinar Carcinoma; Spitzoid Malignant Melanoma; Bladder Cancer; Bladder Urothelial Carcinoma; MAP Kinase Family Gene Mutation; RAS Mutation; RAF Mutation; MEK Mutation
Interventions: Drug: Tovorafenib; Drug: Pimasertib
Sponsors: Day One Biopharmaceuticals, Inc.
Active, not recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Posted: April 26th, 2021, 11:00pm UTC

Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Olaparib; Drug: Placebo Administration
Sponsors: National Cancer Institute (NCI)
Recruiting
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Posted: January 31st, 2020, 1:00am UTC

Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsors: Poseida Therapeutics, Inc.
Terminated
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Posted: November 4th, 2019, 1:00am UTC

Conditions: Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Breast Cancer Metastatic; Breast Cancer Stage IV; Pancreatic Cancer Stage IV; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Adenocarcinoma of the Breast; PALB2 Gene Mutation
Interventions: Drug: Melphalan; Drug: BCNU; Drug: Vitamin B12B; Drug: Vitamin C; Drug: Ethanol; Device: Autologous Hematopoietic Stem Cells
Sponsors: General Oncology, Inc.; Myriad Genetics, Inc.
Recruiting
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Posted: November 14th, 2018, 1:00am UTC

Conditions: Malignant Solid Tumors; Other Neoplasms Solid Tumors; Pediatric Solid Tumor; Refractory Solid Tumors; Solid Tumor
Sponsors: National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 11:00pm UTC

Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Neoplasm of Unknown Primary; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography Test; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Posted: May 2nd, 2016, 11:00pm UTC

Conditions: Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm; Periampullary Adenocarcinoma
Interventions: Procedure: Pancreatectomy; Other: Lavage; Procedure: Pancreatectomy; Other: Lavage; Procedure: Pancreatectomy
Sponsors: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Posted: April 8th, 2009, 11:00pm UTC

Conditions: Adult Solid Neoplasm; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Other: Diagnostic Laboratory Biomarker Analysis; Drug: Erlotinib Hydrochloride; Drug: Gemcitabine Hydrochloride; Drug: Vismodegib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Posted: April 30th, 2008, 11:00pm UTC

Conditions: Locally Advanced Pancreatic Adenocarcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Biological: Falimarev; Biological: Inalimarev; Other: Laboratory Biomarker Analysis; Biological: Sargramostim
Sponsors: National Cancer Institute (NCI)
Active, not recruiting

← PubMed - Acinar Cell Carcinoma Google - Acinic Cell Carcinoma →

Rare Cancer News & Clinical Trials » Trial - Acinar Cell Carcinoma

Feeds

Trial - Acinar Cell Carcinoma (14 unread)

Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population

Posted: April 15th, 2024, 11:00pm UTC

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

Posted: December 7th, 2023, 1:00am UTC

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Posted: November 3rd, 2023, 11:00pm UTC

Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma

Posted: April 26th, 2023, 11:00pm UTC

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Posted: March 18th, 2022, 11:00pm UTC

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Posted: August 2nd, 2021, 11:00pm UTC

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Posted: April 26th, 2021, 11:00pm UTC

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Posted: January 31st, 2020, 1:00am UTC

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Posted: November 4th, 2019, 1:00am UTC

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Posted: November 14th, 2018, 1:00am UTC

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 11:00pm UTC

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Posted: May 2nd, 2016, 11:00pm UTC

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Posted: April 8th, 2009, 11:00pm UTC

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Posted: April 30th, 2008, 11:00pm UTC